Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer (TOPICAL)

This study has been completed.
Cancer Research UK
Roche Pharma AG
Information provided by (Responsible Party):
University College, London Identifier:
First received: January 10, 2006
Last updated: December 1, 2014
Last verified: December 2011

January 10, 2006
December 1, 2014
April 2005
April 2009   (final data collection date for primary outcome measure)
Overall survival [ Time Frame: between date of randomisation and date of death from any cause ] [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT00275132 on Archive Site
  • Progression free survival [ Time Frame: from the date of randomisation to the date of first clinical evidence of progressive disease, or death. ] [ Designated as safety issue: No ]
  • Adverse events/Toxicity [ Time Frame: during and for 28 days following Tarceva/placebo treatment ] [ Designated as safety issue: Yes ]
  • Quality of life [ Time Frame: between randomisation and 8 weeks. ] [ Designated as safety issue: No ]
    QL will be measured using the patient-completed EORTC-QLQ C30 and lung cancer module (LC 14). The primary QL outcome measures will be changes in overall QL and the five most commonly reported lung cancer symptoms (fatigue, breathlessness, cough, emotional functioning and pain).
  • Cost-effectiveness [ Time Frame: from date of randomisation to death ] [ Designated as safety issue: No ]
    Effectiveness will be estimated in terms of quality-adjusted life years. Mean survival will be calculated on the basis of observed mortality (i.e. a within-trial estimate) and by extrapolating the survival curves if some patients remain alive at the end of the trial.
Not Provided
Not Provided
Not Provided
Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
A Randomised, Placebo-Controlled Trial of Erlotinib in Patients With Advanced NSCLC Unsuitable for Chemotherapy

RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether erlotinib is more effective than a placebo in treating non-small cell lung cancer.

PURPOSE: This randomized phase III trial is studying erlotinib to see how well it works compared to a placebo in treating patients with stage III or stage IV non-small cell lung cancer.



  • Compare survival of patients with stage IIIB or IV non-small cell lung cancer that is not suitable for first-line chemotherapy treated with erlotinib vs placebo.


  • Compare progression-free survival and response rate.
  • Compare toxicity.
  • Compare the quality of life.
  • Compare cost-effectiveness.

OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive oral erlotinib once daily for up to 24 months.
  • Arm II: Patients receive oral placebo once daily for up to 24 months. Quality of life is assessed periodically.

After completion of study treatment, patients are followed periodically for survival.

Peer Reviewed and Funded or Endorsed by Cancer Research UK

PROJECTED ACCRUAL: A total of 664 patients will be accrued for this study.

Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Lung Cancer
  • Drug: erlotinib hydrochloride
    Tarceva (OSI-774, erlotinib) PO 150 mg daily
    Other Names:
    • OSI-774
    • Tarceva
  • Drug: Matched placebo
    Matched placebo PO daily
  • Experimental: Erlotinib
    Tarceva (OSI-774, erlotinib) PO 150mg daily
    Intervention: Drug: erlotinib hydrochloride
  • Placebo Comparator: Matched placebo
    Matched placebo PO daily
    Intervention: Drug: Matched placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
April 2009
April 2009   (final data collection date for primary outcome measure)


  • Histologically or cytologically confirmed non-small cell lung cancer

    • Advanced disease (stage IIIB or IV)
    • Diagnosis within 62 days prior to randomization
  • Not suitable for first-line chemotherapy, as defined by the following criteria*:

    • ECOG performance status 2-3
    • ECOG performance status 0-1 AND creatinine clearance < 60 mL/min
  • NOTE: *These criteria do not imply that all such patients are unsuitable for chemotherapy; patients are considered unsuitable on a case by case basis
  • No symptomatic brain metastases


  • Estimated life expectancy of at least 8 weeks
  • Able to take oral medication
  • Not pregnant or nursing
  • Fertile patients must use effective contraception
  • No severe uncontrolled infection
  • No unstable angina
  • No myocardial infarction within the past month
  • No uncontrolled inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis)
  • No acute renal failure
  • Bilirubin < 2 times upper limit of normal (ULN)
  • Transaminases < 2 times ULN (5 times ULN if liver metastases are present)
  • Creatinine < 5 times ULN
  • No evidence of other significant laboratory finding or uncontrolled medical illness that would interfere with study treatment or results comparison or render the patient at high risk from treatment complications
  • No other prior or current malignant disease likely to interfere with study treatment or comparisons


  • No prior chemotherapy
  • No prior biological anticancer therapy (e.g., gefitinib, thalidomide, or cetuximab)
  • No prior palliative radiotherapy

    • Prior palliative radiotherapy to bone metastases allowed within the past 2 weeks
  • No concurrent cyclooxygenase-2 inhibitors
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United Kingdom
CDR0000457755, LLCG-TOPICAL, EU-20313, ISRCTN, Cancer Research UK (CTAAC), Roche AG Pharma, UCL Trial Sponsor reference, EudraCT number
Not Provided
Not Provided
University College, London
University College, London
  • Cancer Research UK
  • Roche Pharma AG
Study Chair: Siow M Lee, MD, PhD, FRCP University College London Hospitals
University College, London
December 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP